Details

Autor(en) / Beteiligte

• Suárez-Fuentetaja, Natalia
• Barge-Caballero, Eduardo
• Bayés-Genís, Antoni
• Doménech, Nieves
• Moreda-Santamaría, Lucía
• Paniagua-Martín, María J
• Barge-Caballero, Gonzalo
• Couto-Mallón, David
• Solla-Buceta, Miguel
• Estévez-Cid, Francisco
• Cuenca-Castillo, José J
• Pombo-Otero, Jorge
• Grille-Cancela, Zulaika
• Blanco-Canosa, Paula
• Muñiz, Javier
• Vázquez-Rodríguez, José Manuel
• Crespo-Leiro, María G

Titel

Circulating Galectin-3 Following Heart Transplant: Long-Term Dynamics and Prognostic Value

Ist Teil von

• Revista española de cardiología (English ed.), 2019-11, Vol.72 (11), p.899-906

Ort / Verlag

Spain: Elsevier España, S.L.U

Erscheinungsjahr

2019

Quelle

MEDLINE

Beschreibungen/Notizen

• Abstract Introduction and Objectives Circulating galectin-3 (Gal-3) is elevated and significantly correlates with all-cause and cardiovascular mortality in patients with heart failure. However, the relationship between serum Gal-3 and heart transplant (HT) outcomes is unclear. The aim of this study was to describe the longitudinal trend and prognostic value of Gal-3 levels after HT. Methods Banked serum samples were available from 122 HT recipients, collected before transplant and at 1, 3, 6, and 12 months posttransplant. Gal-3 levels in these serum samples were measured by enzyme immune assay. Multivariable Cox regression was performed to determine the prognostic value of 12-month posttransplant Gal-3 serum levels. The primary endpoint was the composite variable all-cause death or graft failure over long-term posttransplant follow-up. Results Circulating Gal-3 concentration steadily decreased during the first year after HT (median values: pretransplant, 19.1 ng/mL; 1-year posttransplant, 14.6 ng/mL; P < .001). Circulating Gal-3 levels 1-year posttransplant were associated with an increased risk of all-cause death or graft failure (adjusted HR per 1 ng/mL, 1.04; 95%CI, 1.01-1.08; P = .008). The predictive accuracy of this biomarker was moderate (area under the receiver-operator curve 0.72 (95%CI, 0.60-0.82; P < .001). Conclusions Circulating Gal-3 steadily decreased during the first year after HT. However, 1-year posttransplant Gal-3 serum levels that remained elevated were associated with increased long-term risk of death and graft failure.